Small molecule fusion inhibitors: Design, synthesis and biological evaluation of (Z)-3-(5-(3-benzyl-4-oxo-2-thioxothiazolidinylidene)methyl)-N-(3-carboxy-4-hydroxy)phenyl-2,5-dimethylpyrroles and related derivatives targeting HIV-1 gp41
作者:Xiao-Yang He、Lu Lu、Jiayin Qiu、Peng Zou、Fei Yu、Xing-Kai Jiang、Lin Li、Shibo Jiang、Shuwen Liu、Lan Xie
DOI:10.1016/j.bmc.2013.04.046
日期:2013.12
By a scaffold elongation strategy, a series of (Z)-3-(5-(3-benzyl-4-oxo-2-thioxothiazolidinylidene)methyl)-N-(3-carboxy-4-hydroxy)phenyl-2,5-dimethylpyrroles and related derivatives with a linear multi-aromatic-ring skeleton were designed, synthesized, and evaluated in HIV-1 gp41 and cellular assays. Among them, the most active compounds, 12e, 12g, and 12k with a one-carbon linker (n = 1) between the
通过支架伸长策略,一系列的(Z)-3-(5-(3-苄基-4-氧代-2-硫代噻唑并亚吡啶基亚甲基)甲基)-N-(3-羧基-4-羟基)苯基-2,5设计,合成并在HIV-1 gp41和细胞分析中评估了具有线性多芳族环骨架的-二甲基吡咯和相关衍生物。其中,活性最高的化合物12e,12g和12k 在若丹宁(C)和苯基(D)环之间具有一个碳原子的连接基(n = 1),表现出非常有希望的抑制效能,IC 50值为1.8– 2.6μM和EC 50值分别针对MT-2细胞中gp41 6-HB的形成和HIV-1复制的0.3-1.5μM的值。此外,它们对T20敏感和耐药菌株几乎同样有效。相关的SAR研究和分子建模结果为进一步开发针对HIV-1 gp41的新型非肽小分子融合抑制剂提供了潜力。